Stock Information
Jazz Pharmaceuticals PLC (JAZZ)
Ticker Symbol: JAZZ
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $11,360.04 mil
Piotroski score: 4
PE Ratio: N/A
EPS (TTM): -5.8455
Revenue (TTM): $69.89 M
Dividend Yield: N/A%
ROE: -8.82%
Latest News
-
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Fri, May 1, 2026 4:39 PM
-
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
Thu, Apr 30, 2026 12:00 PM
-
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative
Mon, Apr 27, 2026 11:06 PM
-
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
Mon, Apr 27, 2026 11:00 PM
-
Jazz Pharmaceuticals shares are trading higher after the company announced that the FDA accepted for filing with Priority Review the supplemental Biologics License Application for Ziihera.
Mon, Apr 27, 2026 11:47 AM
-
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Mon, Apr 27, 2026 11:45 AM
-
Jazz Pharmaceuticals announces FDA acceptance and Priority Review of supplemental biologics license application for Ziihera®
Mon, Apr 27, 2026 9:17 AM
-
Jazz Pharmaceuticals Announces FDA Acceptance For Filing With Priority Review Of Supplemental Biologics License Application For Ziihera To Treat Adult Participants With HER2-Positive Unresectable Locally Advanced Or Metastatic Gastric, Gastroesophageal Junction Or Gastroesophageal Adenocarcinoma
Mon, Apr 27, 2026 7:48 AM
Key Financials
Financial data not available
